Skip to content

Valeant debt buy repeated by Goldman

June 2, 2017

Goldman Sachs Credit Research analyst Shubhomoy Mukherjee says Valeant Pharmaceuticals’ (VRX +4.3%) credit story remains optimistic because it should be able to progressively pay down debt via cash on hand, free cash flow, asset sales and available (but limited) secured debt capacity while likely to refinance maturities until fiscal 2020.

Debt payments through 2020 total a bit over $7B while cash from operations, cash on hand and asset sales should tally about the same amount or slightly more.

He adds that he is “cautious” about the company’s 2017 guidance citing soft Xifaxan prescription trends (down 2% yoy) but the dermatology franchise remains stable.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: